BRPI0415678A - pyrimidine compounds for treating inflammation - Google Patents

pyrimidine compounds for treating inflammation

Info

Publication number
BRPI0415678A
BRPI0415678A BRPI0415678-1A BRPI0415678A BRPI0415678A BR PI0415678 A BRPI0415678 A BR PI0415678A BR PI0415678 A BRPI0415678 A BR PI0415678A BR PI0415678 A BRPI0415678 A BR PI0415678A
Authority
BR
Brazil
Prior art keywords
pyrimidine compounds
treating inflammation
compounds
pyrimidine
inflammation
Prior art date
Application number
BRPI0415678-1A
Other languages
Portuguese (pt)
Inventor
Michael Clare
Timothy J Hagen
Stephen C Houdek
Patrick J Lennon
Richard M Weier
Xiangdong Xu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0415678A publication Critical patent/BRPI0415678A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"COMPOSTOS DE PIRIMIDINA PARA O TRATAMENTO DE INFLAMAçãO". São revelados compostos de Fórmula I: em que A, X, R¬ 2¬ e R¬ 4¬ são conforme aqui definidos."PYRIMIDINE COMPOUNDS FOR INFLAMMATION TREATMENT". Compounds of Formula I are disclosed: wherein A, X, R 2 and R 4 are as defined herein.

BRPI0415678-1A 2003-10-23 2004-10-11 pyrimidine compounds for treating inflammation BRPI0415678A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51377003P 2003-10-23 2003-10-23
PCT/IB2004/003314 WO2005040133A1 (en) 2003-10-23 2004-10-11 Pyrimidine compounds for the treatment of inflammation

Publications (1)

Publication Number Publication Date
BRPI0415678A true BRPI0415678A (en) 2006-12-19

Family

ID=34520134

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415678-1A BRPI0415678A (en) 2003-10-23 2004-10-11 pyrimidine compounds for treating inflammation

Country Status (6)

Country Link
EP (1) EP1678146A1 (en)
JP (1) JP2007509126A (en)
BR (1) BRPI0415678A (en)
CA (1) CA2542514A1 (en)
MX (1) MXPA06004498A (en)
WO (1) WO2005040133A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102005025225A1 (en) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
MX2009003793A (en) 2006-10-09 2009-12-14 Takeda Pharmaceutical Kinase inhibitors.
JP2011032169A (en) * 2007-12-11 2011-02-17 Genecare Research Institute Co Ltd 4-aminopyrimidine derivative and medicinal composition containing the compound
DE102007061756A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 4-aminopyrimidine-5-carboxylic acids and their use
CN102458402B (en) 2009-06-12 2013-10-02 百时美施贵宝公司 Nicotinamide compounds useful as kinase modulators
SG181504A1 (en) 2009-12-23 2012-07-30 Sanofi Sa Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
US8685993B2 (en) 2010-12-21 2014-04-01 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
WO2017088755A1 (en) * 2015-11-23 2017-06-01 Suzhou Yunxuan Yiyao Keji Youxian Gongsi Aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD236310A1 (en) * 1984-08-23 1986-06-04 Univ Leipzig PROCESS FOR PREPARING 2,6-DIARYL SUBSTITUTED 4-ARYLAMINO-PYRIMIDIN-5-CARBOXYLIC ACID ESTERS
JP2001089452A (en) * 1999-09-22 2001-04-03 Sankyo Co Ltd Pyrimidine derivative
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2474578C (en) * 2002-02-13 2009-08-25 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2005040133A1 (en) 2005-05-06
JP2007509126A (en) 2007-04-12
EP1678146A1 (en) 2006-07-12
MXPA06004498A (en) 2006-06-20
CA2542514A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
BR0209127A (en) compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR0209129A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds.
BR0309355A (en) 2- (2,6-dichlorophenyl) diarylimidazoles
BR0316487A (en) Whole method of treating transplant rejection
EA200700851A1 (en) OBTAINING AND APPLICATION OF BIPHENYL-4-ILKARBONYLAMINO ACID DERIVATIVES FOR TREATMENT OF OBESITY
ATE408601T1 (en) FREDERICAMYCIN DERIVATIVES
DK1519724T3 (en) Fredericamycin derivatives as drugs for the treatment of tumors
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
DK1558579T3 (en) N-alkyl-4-methylenamino-3-hydroxy-2-pyridones as antimicrobials
EA201000563A1 (en) TRIAZOLPYRIDINE INHIBITORS 11-BETA-HYDROXYSTEROID - DEHYDROGENASE TYPE I
ECSP056210A (en) PREPARATION AND USE OF RENTAL DERIVATIVES FOR THE TREATMENT OF OBESITY
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
BR0309343A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
EA200802213A1 (en) METHODS OF TREATING BLOOD DISEASES
HK1079522A1 (en) Thienyl compounds
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
ATE525067T1 (en) AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULPHONES FOR THE TREATMENT OF PROLIFETING DISEASES
BRPI0410669A (en) caspase inhibitors and their uses
BRPI0511138A (en) pyrimidine derivatives for the treatment of abnormal cell development
BRPI0415678A (en) pyrimidine compounds for treating inflammation
BRPI0416030A (en) hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
BR0209128A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
MXPA05013751A (en) Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof.
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
BR0208499A (en) 3-heterocyclylpropanohydroxamic acid as procollagen c-proteinase inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired